KRAS G12D-targeted protein degrader setidegrasib showed antitumor activity with tolerable safety profile in patients with ...

Amini: I believe this is critical for all stages of NSCLC. Whether you are in a small rural practice, large community or academic setting, having a team that you can communicate with is critical.

Medically reviewed by Doru Paul, MD Key Takeaways Survival rates for stage 3 lung cancer can vary between 13% to 36% depending on the subtype.Stage 3a lung cancer is often treated with surgery and ...

The KRAS p.G12D variant occurs in 5% of patients with non–small-cell lung cancer (NSCLC) and is the most common substitution variant in pancreatic ductal adenocarcinoma, occurring in 40% of ...

Patterns of confirmatory germline testing in patients with somatic BRCA1/2 pathogenic variants across solid tumor types in a community oncology setting. Risk of hypertension in patients newly ...

Our scalable NLP system enabled us to generate real-world insights into NSCLC recurrences, paving the way for predictive models for preventing, diagnosing, and treating NSCLC recurrence. Our NLP ...

Stereotactic ablative radiotherapy (SABR) offers patients with early-stage non-small cell lung cancer (NSCLC) an effective alternative to the standard of care surgery — with significantly fewer severe ...

You and your family are our top priority. At Fred Hutch Cancer Center, we offer comprehensive and compassionate care — personalized to you. You'll have access to the latest treatment options, clinical ...

Racial disparities persist in receipt of curative treatment for early-stage non-small cell lung cancer (NSCLC), according to a study published online March 2 in JAMA Network Open. Olivia F. Lynch, M.D ...

Lung cancer is often misunderstood, leading to delayed diagnosis and missed treatment opportunities. Experts debunk myths ...

Ho: Looking ahead, there are several areas that seem particularly promising. Advances in robotic bronchoscopy platforms, ...